Inspire Trust Co. N.A. Makes New Investment in Zoetis Inc. $ZTS

Inspire Trust Co. N.A. bought a new stake in shares of Zoetis Inc. (NYSE:ZTS) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 55,000 shares of the company’s stock, valued at approximately $3,841,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. University of Texas Texas AM Investment Management Co. bought a new position in shares of Zoetis in the 2nd quarter worth $25,000. Dunhill Financial LLC lifted its stake in shares of Zoetis by 519.3% during the 2nd quarter. Dunhill Financial LLC now owns 353 shares of the company’s stock worth $25,000 after purchasing an additional 296 shares during the last quarter. Cassaday & Co Wealth Management LLC bought a new stake in Zoetis during the first quarter valued at about $28,000. Wellington Grp LLC boosted its position in Zoetis by 6,675.0% during the first quarter. Wellington Grp LLC now owns 271 shares of the company’s stock valued at $32,000 after purchasing an additional 267 shares in the last quarter. Finally, Provenance Wealth Advisors LLC boosted its position in Zoetis by 1,866.7% during the third quarter. Provenance Wealth Advisors LLC now owns 531 shares of the company’s stock valued at $37,000 after purchasing an additional 504 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Up 0.2%

Shares of Zoetis stock opened at $82.48 on Wednesday. The firm’s 50 day simple moving average is $75.88 and its two-hundred day simple moving average is $92.18. The firm has a market capitalization of $33.51 billion, a price-to-earnings ratio of 14.03, a PEG ratio of 1.19 and a beta of 0.67. Zoetis Inc. has a 12-month low of $68.77 and a 12-month high of $132.49. The company has a current ratio of 2.35, a quick ratio of 1.40 and a debt-to-equity ratio of 2.51.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, November 5th. The company reported $1.75 EPS for the quarter, topping the consensus estimate of $1.51 by $0.24. The business had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 26.15% and a return on equity of 85.90%. The business’s revenue for the quarter was down 1.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.70 earnings per share. Analysts predict that Zoetis Inc. will post 6.29 EPS for the current year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 1st. Investors of record on Friday, October 30th will be paid a $0.53 dividend. The ex-dividend date is Friday, October 30th. This represents a $2.12 dividend on an annualized basis and a yield of 2.6%. Zoetis’s dividend payout ratio (DPR) is 36.05%.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Cantor Fitzgerald set a $94.00 target price on shares of Zoetis in a report on Tuesday, August 25th. TD Cowen lowered their price target on shares of Zoetis from $104.00 to $94.00 and set a “buy” rating on the stock in a report on Tuesday, August 25th. UBS Group lifted their price objective on shares of Zoetis from $80.00 to $85.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 27th. BNP Paribas Exane cut their price objective on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 11th. Finally, Piper Sandler reduced their price objective on shares of Zoetis from $90.00 to $80.00 and set a “neutral” rating for the company in a research note on Monday, August 10th. Eight equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Zoetis currently has an average rating of “Hold” and a consensus price target of $101.25.

Zoetis Company Profile

Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish. The company’s offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.